Blood Tests May Offer ‘Breakthrough’ in Diagnosing Alzheimer’s, but Will They Be Covered?

  • Oct 11, 2024

    Blood-based marker tests (BBMTs) may help clinicians more accurately and easily diagnose people with Alzheimer’s disease and aid in identifying patients who could benefit from two recently approved disease-modifying therapies, according to a viewpoint article published on Sept. 30 in JAMA. The piece’s lead author tells AIS Health that BBMTs could potentially offer a “real breakthrough in access to testing” for Alzheimer’s, although she notes payers have yet to cover the tests and need more clinical evidence before paying for them. 

    The FDA in July approved Kisunla (donanemab), a once-monthly, IV-infused treatment for people with early symptoms of Alzheimer’s. The agency’s decision occurred one year after it fully approved Leqembi (lecanemab), a similar Alzheimer’s drug. Kisunla and Leqembi both aim to slow the progression of Alzheimer’s by removing amyloid plaques from the brain.  

    Read more
    © 2024 MMIT
  • Tim Casey

    Tim has been a reporter and editor for newspapers, websites and magazines for more than 20 years, including 10 years covering health care business topics. He has a deep knowledge of the managed care industry and pharmacy benefit management. He also has experience covering medical conferences and clinical and legislative health care issues. In 2014, the Society for Advancing Business Editing and Writing selected Tim as one of 15 journalists to participate in a national symposium on the Affordable Care Act. Tim has a B.A. in Psychology from the University of Notre Dame and an M.B.A. from Georgetown University.

The Latest
Meet Our Reporters

Meet Our Reporters

×